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Abstract Gene array pro¢ling of RNA from cells engineered
to express a dominant-negative version of the ETS family mem-
ber transcription factor Pea3 (polyomavirus enhancer activator
3) identi¢ed WT1 as a candidate downstream gene. Given the
co-expression of WT1 and Pea3 in developing kidney and breast
tissue undergoing mesenchymal to epithelial transitions, we fur-
ther characterized this potential gene hierarchy. Analysis of the
human WT1 promoter revealed several potential binding sites
for Pea3. Pea3 transactivated the WT1 promoter in transient
transfection assays and bound to speci¢c sites within the WT1
promoter in vitro. Our results position Pea3 upstream of WT1
and de¢ne a gene hierarchy important for mesenchymal^epithe-
lial transitions.
, 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Wilms’ tumor is a pediatric renal malignancy of the kidney,
a¡ecting approximately 1 in 10 000 children before the age of
5 years [1]. WT1, the Wilms’ tumor suppressor 1 gene, was
identi¢ed on the basis of its mutational inactivation in 10^
15% of sporadic Wilms’ tumors [2] and in the germline of
children with a genetic predisposition to Wilms’ tumor [3].
The human WT1 gene, located at chromosome position
11p13, spans approximately 50 kb of genomic DNA and in-
cludes 10 exons which generate four alternatively spliced
mRNAs [4]. WT1 protein isoforms contain a proline/gluta-
mine-rich amino-terminus and four zinc ¢nger motifs at the
carboxy-terminus [4]. The zinc ¢ngers form the DNA binding
domain of WT1 and share homology with the early growth
response 1 (EGR-1) gene family of transcription factors. Con-
sequently, WT1 can bind to, and regulate, the expression of
numerous genes through the GC-rich EGR-1 consensus bind-
ing site (5P-GXGXGGGXG-3P) as well as through a TC-rich
site (5P-TCC-3P)n [5,6]. WT1 has been shown to regulate the
expression of several target genes, including those encoding
growth factors, growth factor receptors, transcription factors,
extracellular/secreted proteins, and cell cycle control proteins
[4].
WT1 expression is detected in several tissues during mam-
malian development and in adulthood [4]. It is expressed dur-
ing all stages of kidney development, becoming restricted to
the podocyte layer of the glomerulus in the mature kidney.
During gonadal development, WT1 is expressed in the uro-
genital ridge and becomes localized to the Sertoli cells of the
testis and the granulosa and epithelial cells of the ovary.
Apart from its expression in the kidney and gonads, WT1 is
also detected in the uterus, spleen, liver, thymus, certain areas
of the brain and spinal cord, in the abdominal wall muscula-
ture, and in the mesothelial linings of organs in the thoracic
and abdominal cavities. Other groups have shown that WT1
is expressed in the stem cells of the bone marrow [7], the
developing epicardium [8] and retina [9], and the mammary
gland [10,11].
Targeted inactivation of WT1 in mice revealed that WT1
serves an important role as a transcription factor regulating
organogenesis during embryonic development. The mice
lacked kidneys, gonads, spleens and adrenal glands, and
also had mesothelial and retinal defects [8,9,12,13]. WT1
null mouse embryos fail to develop a urogenital system and
die in utero at E13.5^E15.5 [12] due to heart malformations
leading to edema. The initial mesenchymal^epithelial interac-
tions that occur during kidney development are arrested in the
WT1 null embryos due to lack of outgrowth of the epithelial
ureteric bud into the metanephric mesenchyme (which nor-
mally expresses WT1) with subsequent apoptotic death of
the mesenchymal cells. The inability of the metanephric mes-
enchyme from WT1 null embryos to respond to inductive
signals [12], as well as the spatial and temporal expression
pattern of WT1 during kidney development [14,15], implicates
WT1 in a unique role controlling mesenchymal^epithelial in-
teractions during development. Although much work has been
done to ascertain WT1’s role in development and tumorigen-
esis, little is known about the developmental regulation of
WT1 expression. WT1 promoter-reporter gene assays have
shown that Pax2 and Pax8, members of the paired-box family
of transcription factors, as well as the ubiquitous transcrip-
tional regulator Sp1, activate the WT1 promoter [16^20]. Fur-
thermore, WT1 appears to be involved in an autoregulatory
loop where it represses its own expression [21].
Pea3 (polyomavirus enhancer activator 3) is a member of
the ETS family of transcription factors [22]. Mouse Pea3 (the
human gene is named ETS translocation variant 4 [ETV4] or
E1A-F) is the founding member of a subfamily of ETS genes,
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which also includes Er81 (ETV1) and Erm (ETV5) (reviewed
in [23]). ETS proteins are de¢ned by an evolutionarily con-
served, approximately 85 amino acid ETS DNA binding do-
main which recognizes an V10 bp motif with a core 5P-
GGAA/T-3P sequence [24]. Sequences £anking this central el-
ement govern the speci¢city of binding by particular ETS
proteins. The ETS domain of each protein is su⁄cient for
sequence-speci¢c DNA binding and studies with Pea3 have
shown that DNA binding by Pea3 is regulated by intramolec-
ular and intermolecular protein^protein interactions [25,26].
The activation domain of Pea3 subfamily members is located
near the amino-terminus and comprises an acidic amino acid
region (reviewed in [23]). In particular, the Pea3 activation
domain spans amino acids 42^85 of the 480 amino acid pro-
tein and is £anked by two regions that independently nega-
tively regulate its activity [25].
The expression patterns of the three Pea3 family members
suggest di¡erent functions for each gene during mouse em-
bryogenesis and indicate that these genes are expressed in
association with proliferation and migration events [27]. In-
terestingly, the three genes are expressed in organs where mes-
enchymal^epithelial interactions occur, such as the lung, the
salivary gland or the kidney. During development of the kid-
ney, Pea3 is continuously expressed in ureteric bud ends and
their adjacent condensed mesenchyme. Just prior to birth,
Pea3 expression becomes restricted to the mesenchymal com-
partment in the cortical nephrogenic zone. Pea3 expression is
no longer detectable in the adult kidney.
During the course of a set of gene expression experiments
undertaken to identify downstream targets of Pea3, the WT1
gene scored positive as a putative target. In this report we
identify and characterize a segment within the WT1 promoter
that contains two Pea3 sites. Overexpression of Pea3 trans-
activates the WT1 promoter in transient transfection assays
and the binding of Pea3 to a speci¢c sequence within the WT1
promoter appears responsible for this transactivation. Our
results suggest an important hierarchy between these two
transcription factors during mesenchymal^epithelial interac-
tions in organogenesis.
2. Materials and methods
2.1. Cell lines, transfections, and CAT assays
Mammary carcinoma cell line MDA-MB-468 (ATCC) was grown
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 Wg/
ml streptomycin and 0.25 Wg/ml fungizone. Cells were incubated at
37‡C in a 5% CO2, humidi¢ed environment. CHO and COS7 cells
(ATCC) were grown at 37‡C with 5% CO2 in K-MEM and DMEM,
respectively, supplemented with 10% heat-inactivated fetal calf serum,
100 U/ml penicillin, and 100 Wg/ml streptomycin. For transactivation
assays, 5U105 cells were transfected with 5 Wg of reporter plasmid and
2^4 Wg of expression plasmid by the calcium phosphate precipitation
method [16,17]. Each DNA precipitate was adjusted to contain an
equal amount of DNA by the addition of the empty expression vector
pRcRSV. Transfection e⁄ciency was controlled for by co-transfection
of 3 Wg of L-actin/L-galactosidase in CHO cells and 1 Wg of CMV/L-
galactosidase in COS7 cells. Transfections were performed in duplicate
and repeated a minimum of three times. Cells were harvested and
assayed for L-galactosidase and chloramphenicol acetyltransferase
(CAT) activity 36^48 h post transfection [16,17]. The extent of each
CAT reaction was monitored by thin-layer chromatography using
silica gel 60 F254 plates to separate the acetylated [14C]chlor-
amphenicol from non-acetylated [14C]chloramphenicol. The percent
conversion for the CAT reactions was quantitated by direct analysis
on a Fujix BAS 2000 phosphoimager.
2.2. Recombinant adenoviruses
Plasmids pMA20 and pBHG10 were generously provided by Dr.
Frank L. Graham (McMaster University, Hamilton, ON, Canada).
Dominant-negative Pea3 (vNPea3En) lacks the activation domain of
Pea3 and includes the repression domain of Drosophila Engrailed
fused to the C-terminus [28]. An adenoviral vector containing
vNPea3En was constructed by homologous recombination between
plasmids pMA20 (carrying vNPea3En) and pBHG10 [29]. Ad-
STOP-vNPea3En carries a loxP-£anked STOP sequence upstream
of vNPea3En that e¡ectively blocks translation of the transgene tran-
script. Ad-STOP-vNPea3En was passaged through CRE-expressing
293 cells resulting in excision of the STOP sequence and packaging
of adenovirus capable of expressing vNPea3En [29]. Expression and
functional activity of the transgene in MDA-MB-468 cells following
infection was con¢rmed by Western blot and luciferase reporter assay,
respectively (Vaz and Hassell, in preparation).
2.3. Microarray analysis
MDA-MB-468 cells were grown to 80% con£uence and infected
with either Ad-STOP-vNPea3En (control) or Ad-vNPea3En (exper-
imental). At 12 h post infection, total RNA was harvested using
TRIzol (Life Technologies) according to the manufacturer’s protocol.
RNA was quanti¢ed by measuring A260 and its quality veri¢ed using
an Agilent 2100 Bioanalyzer. RNA samples were processed for global
gene expression analysis on A¡ymetrix GeneChip Human Genome
HG-U133A arrays (Gene Expression Facility, Ottawa Health Re-
search Institute, Ottawa, ON, Canada). The experiment was repeated
three times; one of the control RNA samples failed to be e⁄ciently
reverse transcribed during the labeling reaction. Data were processed
and analyzed using Microarray Suite 5.0 and Data Mining Tool 3.0.
Data from each array were normalized to an average target intensity
of 150 to control for variances in labeling and hybridization e⁄ciency.
Prior to statistical analysis to identify genes downregulated by
vNPea3En expression, probe sets with absent calls on the control
arrays were omitted. Pairwise comparisons were performed between
each of two control and three experimental samples (six comparisons
in total), generating a signal log ratio and a P value of signi¢cant
change for each probe set. A t-test was also performed on normalized
signal intensities for each probe set assuming unequal variances and a
normal distribution, generating a P value measure of con¢dence. Fold
change was calculated from the ratio of the average of two control
samples to the average of three experimental samples.
2.4. Lightcycler data analysis
RNA Master SYBR Green I mix (Roche Molecular Biochemicals)
was used to set up the lightcycler polymerase chain reaction (PCR).
The ampli¢cation program consisted of 1 cycle of 95‡C for 30 s,
followed by 45 cycles of 95‡C with 1 s hold, 57‡C annealing with 5 s
hold, followed by 72‡C with 10 s hold. Acquisition temperature was at
72‡C. The ampli¢cation was followed by melting curve analysis using
the program run for one cycle at 95‡C with a 5 s hold, 65‡C with 15 s
hold, and 95‡C with 0 s hold at the step acquisition mode. A negative
control without cDNA template was run with every assay to assess
the overall speci¢city.
The mean concentration of L2-microglobulin was used to control
for input cDNA using primers hL2M/F (5P-CACCCCCACTGAAA-
AAGATG-3P) and hL2M/R (5P-GATGCTGCTTACATGTCTCG-3P).
The mean L2-microglobulin cDNA concentration was determined
three times for each sample. A standard curve for WT1 was estab-
lished using a series of two-fold serial dilutions from one of the con-
trol samples (Fig. 1C; control #3) using primers hWT1ex7/S (5P-
TTCATGTGTGCTTACCCAGG-3P) and hWT1ex8/AS (5P-AGTC-
CTTGAAGTCACACTGG-3P). The relative levels of WT1 in the oth-
er control and experimental samples were then determined from this
standard curve and were determined three independent times for each
sample.
2.5. Plasmid constructs
The plasmids pCAT/31101 (containing nucleotides 31101 to +199
of the WT1 promoter) and pCAT/3449 (containing nucleotides 3449
to +199 of the WT1 promoter) were kind gifts from Dr. Grady
Saunders (University of Texas, M.D. Anderson Cancer Center, Hous-
ton, TX, USA). The constructs pCAT/3996, pCAT/3910 and pCAT/
3733 were generated by PCR ampli¢cation using a sense strand oli-
gonucleotide containing a HindIII site overhang and an antisense
FEBS 28109 16-2-04
M.T. Discenza et al./FEBS Letters 560 (2004) 183^191184
oligonucleotide 3P to a unique HindIII site at position 3449. The
following are the sense strand oligonucleotides used for the indicated
constructs: pCAT/3996, hWT1-1S (5P-ataagcttctgagcaaccagaat-3P) ;
pCAT/3910, hWT1-2S (5P-ataagctttcgtatccaaaccc-3P) ; and pCAT/
3733, hWT1-3S (5P-ataagcttaagtgctgctgact-3P). The antisense oligonu-
cleotide used was: hWT1-4AS (5P-agcgcagaaagaactcagtc-3P). The PCR
products were digested with HindIII and cloned into pCAT/3449,
which had also been linearized with HindIII. pCAT/31101/997,
pCAT/3996/911, pCAT/3910/734 and pCAT/3996/734 were con-
structed by PCR ampli¢cation using sense and antisense oligonucleo-
tides with HindIII overhangs. The following are the sense and anti-
sense oligonucleotides used for the indicated constructs: pCAT/
31101/997, hWT1-5S (5P-ataagcttgagctcccaaagat-3P) and hWT1-6AS
(5P-ataagctttgattgaccaggag-3P) ; pCAT/3996/911, hWT1-1S and
hWT1-7AS (5P-ataagcttgcccggcaggga-3P) ; pCAT/3910/734, hWT1-2S
and hWT1-8AS (5P-atatataagcttgtttccctttccag-3P) ; and pCAT/3996/
734, hWT1-1S and hWT1-8AS. Subsequent cloning was carried out
as described for pCAT/3996. Plasmid pCAT/v(P3-2) was made by
performing two separate PCRs, one with hWT1-1S and mutPea3-2/
AS (5P-tggcgcccagtttgggg-3P) and the other with mutPea3-2/S (5P-
ccaaactgggcgccatgctccggccggaatat-3P) and hWT1-8AS. The products
of these PCRs were annealed, extended, and ampli¢ed with hWT1-
1S and hWT1-8AS, digested with HindIII, and cloned into pCAT/
3449 (which had also been linearized with HindIII). Plasmid
pCAT/v(P3-2)(P3-Py) was made by performing two separate PCRs,
one with hWT1-1S and mutPea3-3/AS (5P-agtttggggaggagggg-3P) and
the other with mutPea3-3/S (5P-ctcctccccaaactcaggctttgggcgtttg-3P)
and hWT1-8AS. The products of these PCRs were annealed, ex-
tended, and ampli¢ed with hWT1-1S and hWT1-8AS. The product
was digested with HindIII and cloned into pCAT/3449, which
had been linearized with HindIII. Plasmid pCAT/v(P3-Py) was
made by performing two separate PCRs, one with hWT1-1S and
mutPea3-4/AS (5P-ggccggagcatcctggc-3P) and the other with mut-
Pea3-4/S (5P-aggatgctccggccatatactcaggctttgg-3P) and hWT1-8AS.
The products of these PCRs were then annealed, extended, and am-
pli¢ed with hWT1-1S and hWT1-8AS, digested with HindIII, and
cloned into pCAT/3449 (which had been linearized with HindIII).
All clones were sequenced to verify the integrity of the ampli¢cation
products.
2.6. Western blots and electrophoretic mobility shift assays (EMSA)
CHO and COS7 cells were transfected with 5 Wg of reporter plasmid
and the indicated amounts of pRcRSV/Pea3 expression vector. Cells
were harvested as indicated for the CAT assays and 60 Wg of total
cellular protein was electrophoresed on an 8% sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS^PAGE) gel. The gel was
electroblotted onto polyvinylidene di£uoride (PVDF) membrane and
probed with an anti-Pea3 antibody (Santa Cruz Biotechnology), fol-
lowed by incubation with anti-mouse IgG-horseradish peroxidase-
conjugated antibody, as recommended by the manufacturer (Santa
Cruz Biotechnology). To visualize protein, blots were incubated in
Western Lightning1 Chemiluminescence Reagent Plus according to
the manufacturer’s instructions (Perkin Elmer Life Sciences) and ex-
posed to Kodak X-OMAT ¢lm.
The recombinant fusion protein glutathione S-transferase (GST)-
Pea3 was expressed in BL21 bacterial cells by isopropyl-L-D-thioga-
lactose induction from a GST-based expression vector. The protein
was puri¢ed by a⁄nity chromatography using glutathione-Sepharose
4B beads followed by elution with reduced glutathione, as recom-
mended by the manufacturer (Amersham Pharmacia Biotech). Ap-
proximately 1.5 Wg of GST-Pea3 was incubated for 20 min at room
temperature with 0.04 pmol (30 000^50 000 cpm) of double-stranded
oligonucleotide probes labeled by the Klenow reaction using [K-32P]-
dCTP. Binding reactions contained 10 mM Tris^HCl (pH 7.5), 2 mM
MgCl2, 50 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 5% glyc-
erol, 1 Wg poly[(dIdC)(dIdC)] and 1 Wg salmon sperm DNA. In bind-
ing reactions containing unlabeled, competitor DNA, the protein was
pre-incubated with the indicated molar excess of speci¢c competitor
DNA for 15 min at room temperature prior to the addition of probe.
In supershift reactions, the protein was pre-incubated with the indi-
cated antibody for 15 min at room temperature prior to the addition
of probe. EMSA binding reactions were electrophoresed into 4% poly-
acrylamide/0.5UTBE gels in 0.5UTBE bu¡er (1UTBE is 0.18 M
Tris, 0.18 M boric acid, 4 mM EDTA) at 96 V at room temperature.
Gels were dried and exposed to Kodak X-OMAT ¢lm.
3. Results
3.1. Microarray analysis
In order to identify downstream targets of Pea3, a domi-
nant-negative form, vNPea3En, was expressed in MDA-MB-
468 cells and was expected to reduce expression of genes con-
stitutively activated by endogenous Pea3. MDA-MB-468 cells
were selected for analysis based on their high levels of endog-
enous Pea3 expression [30]. Of the 22 283 probe sets spotted
on the HG-U133A array, 186 probe sets produced normalized
signal intensities demonstrating lower expression (greater than
Fig. 1. A: Western blot analysis of DNPea3En expressed in MDA-
MB-468 infected cells. B: Normalized signal intensities of probe set
corresponding to WT1 mRNA from MDA-MB-468 cells (control)
and vNPea3En-infected MDA-MB-468 cells (experimental) from mi-
croarray experiments. Control and experimental average signal in-
tensities are indicated (solid lines) along with standard deviations
(dotted lines). C: Relative levels of WT1 expression in control
MDA-MB-468 cells (control) or vNPea3En-infected MDA-MB-468
cells (experimental) determined by quantitative PCR. Three indepen-
dent experimental determinations were made and are expressed rela-
tive to the levels obtained with control sample #3. The average er-
ror of the mean is also indicated.
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two-fold) in MDA-MB-468 cells infected with Ad-vNPea3En,
compared to cells infected with the control virus in all six
pairwise comparisons. Of these probe sets, 81 showed statis-
tically signi¢cant (95% con¢dence interval) di¡erential expres-
sion between control and experimental samples by t-test.
Probe set 206067_s_at, corresponding to WT1 transcript var-
iant D mRNA, fell into the last group of probe sets, display-
ing a t-test P value of 0.009 and a fold change of 32.74 (Fig.
1B). This suggested downregulation of WT1 transcripts upon
expression of vNPea3En in MDA-MB-468 cells.
To verify these results, we performed kinetic reverse tran-
scription (RT) PCR analysis (real-time) on three control and
two experimental samples to assess the relative levels of WT1.
Following normalization of all ¢ve samples to L2-microglobu-
lin, the WT1 levels were determined relative to one of the
control samples (Fig. 1C, control #3). Sample control #3
and #2 showed similar levels of WT1 expression, whereas
control sample #1 showed a three-fold lower WT1 level
(Fig. 1C). Both experimental samples showed an eight-fold
decrease in WT1 levels relative to control samples #2 and
#3, and a 2.4-fold decrease relative to control sample #1
(Fig. 1C). These experiments validate the array-based expres-
sion di¡erences observed for WT1 and suggest that WT1 may
reside downstream of Pea3.
Fig. 2. A: Schematic representation of the expression vector and reporter plasmids used in this study. The pRcRSV/Pea3 expression vector con-
tains the murine Pea3 cDNA under control of the RSV promoter to produce a protein of 480 amino acids (66 kDa). The amino-terminal re-
gion of Pea3 contains a 43 amino acid acidic activation domain and the carboxy-terminal region contains the ETS DNA binding domain. The
reporter plasmid, pCAT/31101, contains the human WT1 promoter cloned upstream of the CAT gene in the vector pCAT/Basic. The major
start site of transcription [31] is indicated by an arrow. The putative Pea3 binding sites within the WT1 promoter identi¢ed by TESS, and their
positions relative to the start site of transcription, are indicated and labeled P3-1 to P3-5 and P3-Py. B: Activation of the WT1 promoter by
Pea3. Co-transfections in CHO and COS7 cells were performed with 5 Wg of reporter plasmid and increasing amounts of pRcRSV/Pea3 expres-
sion vector. The fold transactivation was calculated by taking the CAT activity obtained in the presence of the indicated amount of pRcRSV/
Pea3 relative to the activity obtained in the absence of pRcRSV/Pea3, which was set as 1. Error bars represent the S.E.M. obtained from three
experiments (performed in duplicate). C: Western blot analysis of Pea3 in transfected cells. Whole cell protein extracts (from B) were separated
by SDS^PAGE, transferred onto a PVDF membrane, and blotted with anti-Pea3 antibody. The amount of Pea3 expression vector titrated into
the transfections is indicated below the panel. The cellular origin of the lysates is indicated above the panel.
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3.2. Identi¢cation of Pea3 sites within the WT1 promoter
To characterize the potential regulation of WT1 by Pea3,
we analyzed the WT1 promoter for candidate Pea3 binding
sites. The human WT1 promoter lacks a TATA box or
CCAAT motif and has a GC content of 71% [31]. Four tran-
scriptional start sites clustering within a 32 bp region have
been previously identi¢ed by mung bean nuclease mapping
[31]. The major transcription start site corresponding to the
strongest nuclease-resistant band was designated +1. The
WT1 upstream region of 31101 to +199 was submitted to
the TESS-String-Based Search that used the TRANSFAC
v3.2 database (www.cbil.upenn.edu/tess) for analysis of poten-
tial transcription factor binding sites. Five putative Pea3 bind-
ing sites were identi¢ed at positions 31018, 3863, 3695,
3424 and +78 and were named P3-1 to P3-5 (Fig. 2A). Addi-
tionally, a sixth potential Pea3 binding site was identi¢ed at
3851 (P3-Py) upon visual inspection of the WT1 promoter
(Fig. 2A).
3.3. Transactivation of the WT1 promoter by transient
expression of Pea3
To assess whether any of the identi¢ed Pea3 binding sites in
the WT1 upstream region were functional, a WT1/CAT re-
porter vector (pCAT/31101) containing sequences from nu-
cleotides 31101 to +199 was co-transfected with increasing
amounts of RSV/Pea3 expression vector into CHO or COS7
cells to gauge the activation potential of Pea3 (Fig. 2B). Ti-
tration of pRcRSV/Pea3 into CHO cells produced a ¢ve-fold
transactivation of the pCAT/31101 promoter at V4 Wg of
input pRcRSV/Pea3 (Fig. 2B), whereas transactivation of
the control pCAT/Basic vector was a¡ected only slightly
(two-fold) by the presence of Pea3 (Fig. 2B). A similar dose
response with pRcRSV/Pea3 was obtained in COS7 cells, with
the exception that a higher activation (seven-fold) was ob-
tained with 4^8 Wg of pRcRSV/Pea3 (Fig. 2B). No e¡ect of
pRcRSV/Pea3 on the promoterless pCAT/Basic vector was
noted in COS7 cells (Fig. 2B). Western blotting analysis per-
formed on total cellular protein extracts from transfected
CHO and COS7 cells revealed a quantitative increase in
Pea3 protein expression upon titration of pRcRSV/Pea3, as
expected (Fig. 2C).
3.4. Identi¢cation of a Pea3 responsive element within the WT1
promoter
To determine which of the six putative Pea3 binding sites
within the 31101 to +199 WT1 promoter region were medi-
ating Pea3 transactivation, a series of promoter deletion con-
structs were cloned into the CAT reporter plasmid. CHO and
COS7 cells were transfected with these in conjunction with a
¢xed amount of pRcRSV/Pea3 expression vector (Fig. 3A).
The deletion mutant pCAT/3996 was responsive to Pea3 in
CHO and COS7 cells, whereas pCAT/3733, pCAT/3449, and
pCAT/3996/911 were not responsive to Pea3 in CHO cells
(background activation in CHO cells is Vtwo-fold [Fig.
2B]) whereas their responsiveness decreased (2.3^3.3-fold),
but was not abolished, in COS7 cells (Fig. 3A). The results
from these deletion mutants suggested that (a) Pea3 site(s)
should reside between nucleotides 3910 and 3734. This was
directly tested with constructs pCAT/3910/734 and pCAT/
3996/734, in which this region (nucleotides 3910 to 3734
or nucleotides 3996 to 3734) was grafted onto pCAT/
3449. Both constructs showed responsiveness to Pea3 in
CHO and COS7 cells to levels that resembled those obtained
with pCAT/3996 (Fig. 3A).
Fig. 3. Analysis of WT1 promoter deletion mutants for Pea3 transactivation. A: Schematic diagram showing WT1 promoter deletion con-
structs. The empty boxes represent the WT1 promoter and the blackened boxes represent the CAT gene. The nucleotide positions of the WT1
promoter sequences contained in each deletion construct are indicated above the boxes. B: The sequence of deletion mutants within two poten-
tial Pea3 sites at nucleotides 3996 to 3734 are shown above the constructs pCAT/v(P3-2), pCAT/v(P3-2)(P3-Py) and pCAT/v(P3-Py). A dot-
ted line refers to an internal deletion. Adjacent to each reporter construct is the fold transactivation and the S.E.M. (obtained from at least
three experiments, each done in duplicate). The fold transactivation was calculated by taking the CAT activity obtained with the reporter con-
struct in the presence of the expression plasmid (pRcRSV/Pea3), and dividing by the activity obtained with the reporter in the presence of the
empty expression vector.
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The sequence between nucleotides 3910 and 3734 contains
two potential Pea3 binding sites ^ P3-2 and P3-Py (Fig. 2A).
To assess the contribution of these sites to the Pea3 trans-
activation response, reporter plasmids containing mutations
at one or both sites were constructed into the pCAT/3996/
734 reporter backbone. Deletion of both Pea3 sites generated
a reporter, pCAT/v(P3-2)(P3-Py), that was no longer respon-
sive to Pea3 in CHO and COS7 cells (Fig. 3B). The reporter
pCAT/v(P3-Py) was not responsive to Pea3 in CHO cells
since the level of activation obtained (two-fold) is similar to
levels obtained with the promoterless pCAT/Basic reporter
(Fig. 2B). However, in COS7 cells this promoter was still
responsive to Pea3. Deletion of the P3-2 site generated a re-
porter, pCAT/v(P3-2), that was responsive to Pea3 in both
CHO and COS7 cells (Fig. 3B). The response in COS7 cells
was 61% of control levels (i.e. pCAT/3996/734). We interpret
these results to indicate that the P3-Py site is required for full
responsiveness to Pea3 in CHO cells, whereas in COS7 cells,
both P3-2 and P3-Py appear to be required for the full re-
sponse.
3.5. Binding of Pea3 to the nucleotide sequences de¢ning the
P3-Py site
To assess whether Pea3 could interact directly with sequen-
ces within the WT1 promoter, we performed a series of mo-
bility shift assays with an oligonucleotide containing both the
P3-2 and P3-Py sites (called Pea3-2 in Fig. 4A) and recombi-
nant GST-Pea3 protein. Recombinant Pea3 (as opposed to
cell extracts) was utilized in the EMSA to ensure that only
WT1 promoter/Pea3 interactions would be directly analyzed,
and not interactions of other ETS protein members with the
WT1 promoter. As positive and negative controls of speci¢c
DNA binding, we used oligonucleotides containing an opti-
mal Pea3 binding site (called Pea3 in Fig. 4A) and an oligo-
nucleotide with a mutated Pea3 binding site (called Mut1 in
Fig. 4A). Incubation of GST-Pea3 with radiolabeled Pea3-2
produced a single complex (indicated by an arrow in Fig. 4B;
compare lane 1 to 9). This complex can be speci¢cally com-
peted by increasing amounts of unlabeled Pea3-2 oligonucleo-
tide (Fig. 4B, lanes 2^6) and by 100-fold excess of Pea3 oli-
gonucleotide (Fig. 4B, lane 7), but not by 100-fold excess of
Mut1 oligonucleotide (Fig. 4B, lane 8). These results indicate
that the complex formed by GST-Pea3 on the Pea3-2 oligo-
nucleotide is speci¢c.
To eliminate the possibility that an Escherichia coli protein
contaminating the GST-Pea3 protein preparation was respon-
sible for the observed complex, we performed the EMSA in
the presence of anti-Pea3 antibodies (Fig. 4C). The mobility
of the GST-Pea3/Pea3-2 complex is shifted to a slower migrat-
ing species in the presence of anti-Pea3 antibodies (Fig. 4C,
compare lane 5 to lane 1). This phenomenon is not observed
in the presence of anti-Sp1 antibodies (Fig. 4C, compare lane
6 to lane 1). These results are consistent with GST-Pea3 being
present in the complex formed on the Pea3-2 oligonucleotide.
GST-vC317 is a carboxy-terminal deletion mutant of GST-
Pea3 that lacks the ETS domain [25] and therefore cannot
form a complex with a Pea3 DNA binding site. Incubation
of GST-vC317 with radiolabeled Pea3-2 did not produce a
complex (Fig. 4C, compare lane 7 to lane 1) indicating that
the ETS domain of Pea3 is involved in binding to the Pea3-2
oligonucleotide. Incubation of GST alone with radiolabeled
Pea3-2 did not produce a complex (Fig. 4C, compare lane 8
with lane 1), indicating that the GST portion of the GST-Pea3
fusion protein is not responsible for the observed complex
between GST-Pea3 and Pea3-2.
To further delineate which of the Pea3 binding sites within
Pea3-2 (and hence between nucleotides 3910 and 3734 of the
WT1 promoter) could interact with Pea3, EMSAs were per-
formed using a series of mutant oligonucleotides as probes
and recombinant GST-Pea3 (Fig. 5). EMSAs performed
with Mut5 (which lacks the P3-2 site) generated a complex
that could not be competed with Mut7 (which lacks both P3-2
and P3-Py sites) but which could be supershifted with anti-
Pea3 antibodies (Fig. 5B, lanes 1^3). The complex formed on
Mut5 behaved similarly to the complex formed on Pea3-2
Fig. 4. EMSA demonstrating speci¢c binding of Pea3 to the WT1
promoter sequences. A: Sequences of the oligonucleotides used to
analyze DNA binding of Pea3. Pea3-2 is an oligonucleotide contain-
ing the putative P3-2 binding site (double underline) identi¢ed by
TESS within the 3996 to 3734 region of the WT1 promoter, and
the P3-Py site (single underline). The Pea3 oligonucleotide contains
a known Pea3 binding site and was used as a positive control
(J. Hassell, personal communication). The core Pea3 site is shown
in bold. Mut1 is an oligonucleotide containing a mutant Pea3 bind-
ing site used as a negative control (sequence underlined, mutation in
bold). B: Pea3 can interact with sequences within the WT1 pro-
moter. Binding of GST-Pea3 to radiolabeled Pea3-2 (lane 1) and
competition of this complex by increasing amounts of unlabeled
Pea3-2 oligonucleotide (lanes 2^6). Binding reactions with radiola-
beled Pea3-2 and competition with oligonucleotide Pea3 (lane 7)
and oligonucleotide Mut1 (lane 8) are also shown. The nature of
the speci¢c competitor oligonucleotide, and the molar amount used
relative to the radiolabeled Pea3-2 probe, is indicated above each re-
action lane. The position of migration of the speci¢c complex is in-
dicated by an arrow and that of the probe shown by an arrowhead.
C: Supershift of the Pea3 complex with an anti-Pea3 antibody. The
nature of the speci¢c competitor oligonucleotide, of the antibody,
and of the GST protein used in the EMSA is indicated. The speci¢c
GST-Pea3/DNA complex is indicated by an arrow, the supershifted
complex by a double arrow, and the free probe by an arrowhead.
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(Fig. 5B, compare lanes 1^3 to lanes 10^12). A faint, di¡use
complex was formed on Mut6 (which lacks the P3-Py site)
(lane 4) and appeared to be speci¢c, as it was not competed
by Mut7 (lane 5) and was supershifted by anti-Pea3 antibodies
(lane 6). Mut7 was unable to form a complex with GST-Pea3
(lanes 7^9). Hence, these data suggest that Pea3 binds prefer-
entially to the P3-2 site.
4. Discussion
The analysis described in this report indicates that the WT1
promoter can be transactivated by Pea3 and that this e¡ect is
mediated through a region containing two Pea3 sites. We
found that the WT1 promoter was responsive to Pea3 in
both CHO and COS7 cells (Fig. 2). To identify the cis-acting
element(s) within the WT1 promoter responsible for mediat-
ing the Pea3 response, we generated a series of deletion con-
structs and assessed their responsiveness to Pea3 (Fig. 3).
These experiments indicated that a single site, P3-Py, could
mediate the Pea3 e¡ect in CHO cells. However, in COS7 cells,
deletion of both P3-2 and P3-Py was necessary to completely
abrogate the Pea3 response (Fig. 3). GST-Pea3 can interact
directly with the P3-Py element, but weakly with the P3-2
element (Figs. 4 and 5) suggesting that in COS7 cells, the
P3-2 site may be used by other ETS family members. Our
experiments also do not exclude the possibility of there being
additional functional Pea3 responsive sites within the WT1
promoter, as is possibly suggested by the ‘residual’ activation
levels observed in COS7 with pCAT/3449 (Fig. 3A).
Our studies de¢ne an additional layer of complexity to the
transcriptional network regulating WT1 expression. Enhancer
and silencer elements have been mapped: (i) 15 kb [32] and
1.3 kb [33] upstream of the WT1 transcription initiation sites,
(ii) within the third intron [33,34], and (iii) downstream of the
WT1 gene [35]. WT1 expression is known to be regulated by
at least six di¡erent transcription factors: Sp1, GATA-1, NF-
UB, WT1, Pax2, and Pax8. Both the human and murine WT1
promoters lack a TATA box and CCAAT site and are GC-
rich [15,31]. DNase I footprinting analysis revealed the pres-
ence of multiple sites within the WT1 regulatory region (pro-
moter and 5P untranslated region [UTR]) protected by Sp1,
and co-transfection experiments con¢rmed the ability of Sp1
to activate through these sites [20,31]. WT1 expression in the
lymphoid system is in£uenced by GATA-1 activation through
hematopoietic-speci¢c enhancers found within the third intron
and within the 3P UTR of the WT1 gene [34,35]. NF-UB
activates WT1 expression through a site downstream of the
WT1 major transcription start site [36], possibly also contrib-
uting to WT1 gene expression during hematopoiesis.
WT1 is thought to repress its own expression by binding to
multiple sites within its regulatory region [21]. Two members
of the Pax family of transcription factors, Pax2 and Pax8, are
also upstream regulators of WT1 gene expression. Studies
with the human and murine promoters have de¢ned Pax8 sites
upstream of the major transcription start site through which
Pax8 can activate the WT1 promoter [16,19]. Pax2 has also
been shown to activate WT1 gene expression. One Pax2 site
has been de¢ned on the murine promoter to be present up-
stream of the major transcription start site, and two other
sites have been de¢ned for the human promoter, one posi-
tioned upstream and the other downstream of the major tran-
scription start site [17,18]. In turn, WT1 has been shown to be
a repressor of the Pax2 promoter [37]. This reciprocal control
of gene expression between WT1 and Pax2 is consistent with
the temporal and spatial pattern of WT1 and Pax2 gene ex-
pression during kidney development [37]. Our results position
Pea3 upstream of WT1 and the next challenge will be to elu-
cidate the interaction network between WT1 trans-acting fac-
tors.
The physiological relevance of WT1 induction by Pea3 may
be quite signi¢cant. The expression patterns of WT1 and Pea3
demonstrate a high degree of coincidence during kidney and
mammary gland development. Additionally, both WT1 and
Pea3 have been implicated in the process of epithelialization
through the regulation of downstream target genes required
for this process. Speci¢cally, both WT1 and Pea3 are ex-
pressed in the condensed mesenchymal cells throughout neph-
rogenesis [14,15,27,38]. In the WT1 knock-out mouse, there is
no outgrowth of the ureteric bud and the mesenchymal cells
fail to di¡erentiate and die due to apoptosis [12]. The inability
of the mesenchymal cells to di¡erentiate and the failure of the
ureteric bud to grow from the Wol⁄an duct are due to an
autonomous cell defect resulting from the loss of WT1 [12].
WT1 therefore plays an important role in allowing mesenchy-
mal^epithelial interactions to occur during the initial stages of
metanephric kidney development. Pea3 is expressed in several
tissues and organs during embryonic development and in the
adult mouse [27]. Within a given developing organ, Pea3Ps
expression coincides with regions of the embryo undergoing
Fig. 5. Analysis of Pea3 binding sites on oligonucleotide Pea3-2. A:
Sequences of the oligonucleotides used to analyze DNA binding of
Pea3. Mut5 is a mutant of the Pea3-2 oligonucleotide containing a
mutation within the P3-2 binding site. Mut6 is a mutant of the
Pea3-2 oligo containing a mutation in the P3-Py binding site. Mut7
is a mutant version of Pea3-2 containing deletions in both the P3-2
and P3-Py sites. B: EMSA using Mut5, Mut6, and Mut7 as probes
to analyze binding by GST-Pea3. EMSAs were performed in the
presence of GST-Pea3 and the indicated oligonucleotides. The na-
ture of the competitor oligonucleotide or antibody used in the
EMSA is indicated above each lane. The speci¢c GST-Pea3/DNA
complex is indicated by an arrow, the supershifted complex by a
double arrow, and the free probe by an arrowhead.
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cellular proliferation and migration. Like WT1, Pea3 is ex-
pressed in tissues and organs at sites of mesenchymal^epithe-
lial transitions, such as the kidney.
Pea3 and WT1 are co-expressed in the myoepithelial cells of
ducts and alveoli of the mammary gland [10,39]. Pea3 is also
expressed in the terminal end buds of the developing mam-
mary gland [27], whereas WT1 is present in less di¡erentiated
cells of the mammary ducts [10]. Since our data suggest that
Pea3 resides upstream of WT1, activation of WT1 by Pea3
may be important for mammary gland homeostasis or regu-
lation of ductal and/or alveolar development. Additionally,
analysis of WT1 and Pea3 expression in mammary tumors
has suggested that these two genes may also have a role in
mammary oncogenesis. Pea3 mRNA levels are increased in
mammary tumors of transgenic mice expressing either the
neu oncogene or the polyomavirus middle T antigen oncogene
under control of the mouse mammary tumor virus promoter
[40]. Similarly, Pea3 mRNA levels are elevated in human
breast tumors [41]. Pea3’s role in tumorigenesis may be
through the regulation of expression of proteases required
for the degradation of the extracellular matrix. Deregulated
expression of such proteases has been associated with the
ability of tumor cells to metastasize [42]. This probably ac-
counts for the metastatic potential of Pea3 overexpressing
cells lines that indeed, also overexpress the matrix metallopro-
teinases (MMPs) MMP-3 and MMP-9 [43]. Ectopic expres-
sion of Pea3 in the human breast cancer cell line MCF7 in-
creases the metastatic potential of these cells [44]. Conversely,
expression of antisense Pea3 in human tumor cells reduces
their invasiveness [45].
On the other hand, studies with WT1 have shown that WT1
expression levels are either upregulated or downregulated in
breast tumors, depending on the tumor type and the stage of
the cancer [10,11]. Furthermore, there is altered expression of
WT1 in certain human breast tumors [10] with some tumor
cells showing cytoplasmic retention, rather than nuclear local-
ization, of WT1. Studies using RT-PCR showed that WT1
transcript levels are elevated in primary carcinomas and inva-
sive ductal carcinomas compared to normal mammary tissue
and have correlated high levels of WT1 mRNA with poorer
prognosis in breast cancer patients [46,47]. WT1 protein levels
were found to be correlated with the proliferation of breast
cancer cells and downregulation of WT1 protein through the
use of antisense oligonucleotides leads to breast cancer growth
inhibition and reduced cyclin D1 protein levels [48]. Hence,
our data would suggest that overexpression of Pea3 in some
breast cancers may be responsible for elevated WT1 levels,
which in turn could contribute to the increased proliferation
of transformed cells.
Unlike the WT1 homozygous null mouse, the Pea3 knock-
out mouse does not have a kidney defect [12,49]. It is possible
that the other Pea3 family members, Erm and Er81, are com-
pensating for the loss of Pea3 during nephrogenesis. Erm is
co-expressed with Pea3 in the condensed metanephric mesen-
chyme during nephrogenesis and Er81 is transiently expressed
in the metanephric mesenchyme, with its expression peaking
at embryonic day 15.5 [27]. Female mice lacking a functional
Pea3 allele of mixed strain background (BALB/c and Sv129)
have reduced postnatal branching of the mammary ductal tree
prior to puberty and during pregnancy, whereas the mam-
mary glands of pubertal PEA3 null mice of pure strain back-
ground (FVB/N) comprise an increased number of terminal
end buds and an increased proportion of proliferating cells in
their terminal end buds [39]. To our knowledge, mammary
duct development has not been closely analyzed in the WT1
knock-out mouse.
During renal development, a constant remodeling of the
extracellular matrix is required to allow invasion and branch-
ing of the ureteric bud in the metanephric mesenchyme, sug-
gesting a role for matrix-degrading enzymes, such as matrix
MMPs. MMP-1 and MMP-9 are expressed in the metanephric
mesenchyme and have been implicated in controlling branch-
ing morphogenesis during kidney development [50,51]. E1A-
F, the human homolog of mouse Pea3, upregulates the ex-
pression of MMP-1, MMP-3 and MMP-9 [52]. Furthermore,
Pea3 activates MMP-7 transcription synergistically with L-cat-
enin-Tcf/LEF-1 (T-cell factor/lymphoid enhancer factor-1)
[53]. Our data place Pea3 upstream of WT1, which in turn
could activate the epithelialization program. WT1 is required
to regulate the expression of syndecan-1 and E-cadherin [54,55]
^ proteins that are necessary for triggering signalling events
during mesenchymal^epithelial transition. Loss of expression
of either gene in epithelial cells causes the cells to lose their
epithelial morphology [56^64]. Hence, the coupling of MMP
activation (by Pea3) and of syndecan-1 and E-cadherin activa-
tion (by WT1) ensures co-incident temporal expression of
both these processes during renal development. Our results
identify Pea3 as a WT1 trans-acting factor, important for
mesenchymal^epithelial transitions.
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